Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Phase III NCT04772079

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis — Recruiting • Phase III…

📅 09 Jun 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase III
NCT ID
NCT04772079
Start
2021-03-23
Completion
2029-01-01
ClinicaliQ Trial Snapshot
  • A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis — Recruiting • Phase III • Rheumatology • NCT04772079.
  • Trial testing deucravacitinib dosing, effectiveness and safety in children aged 4-17 with moderate-to-severe psoriasis over five years.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Podcast
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 00:16:21 · 03 Apr 2026
JAK inhibitors target the JAK-STAT pathway, interrupting intracellular cytokine signalling across several inflammatory diseases. ORAL Surveillance reshaped risk assessment after higher rates…
Listen →
Webinar
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 0.5 · 05 Apr 2026
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL Surveillance safety signals, cardiovascular…
Watch webinar →
Guideline
2023 EULAR Recommendations for Systemic Lupus Erythematosus
Rheumatology · 30 Mar 2026
This EULAR guideline addresses 2023 EULAR Recommendations for Systemic Lupus Erythematosus in Rheumatology. Use it to review current recommendation wording, eligibility criteria,…
View guideline →
Guideline
2022 EULAR Recommendations for the Management of Rheumatoid Arthritis
Rheumatology · 30 Mar 2026
This EULAR guideline addresses 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis in Rheumatology. Use it to review current recommendation wording,…
View guideline →
Guideline
2023 EULAR Recommendations for the Management of Gout
Rheumatology · 30 Mar 2026
This EULAR guideline addresses 2023 EULAR Recommendations for the Management of Gout in Rheumatology. Use it to review current recommendation wording, eligibility…
View guideline →
Guideline
Osteoarthritis: Care and Management (NICE CG177)
Rheumatology · 27 Mar 2026
Offer all patients with osteoarthritis structured information about self-management, weight management, and both land-based and aquatic exercise programmes as first-line treatment before…
View guideline →